AbCellera Biologics (ABCL) Operating Leases (2020 - 2026)

AbCellera Biologics' Operating Leases history runs 7 years deep, the most recent figure standing at $134.3 million for Q1 2026.

• Quarterly Operating Leases rose 112.48% year-over-year to $134.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.3 million (up 112.48% YoY) and the FY2025 annual result came in at $137.4 million, up 126.2% from the prior year.
• Operating Leases was $134.3 million for Q1 2026 at AbCellera Biologics, down from $137.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $137.4 million in Q4 2025 and bottomed at $32.8 million in Q2 2022.
• A 5-year average of $82.1 million and a median of $75.2 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases jumped 162.58% — and 2024, when it fell 21.5%.
• AbCellera Biologics' Operating Leases stood at $76.7 million in 2022, then climbed by 0.92% to $77.4 million in 2023, then decreased by 21.5% to $60.7 million in 2024, then soared by 126.2% to $137.4 million in 2025, then declined by 2.25% to $134.3 million in 2026.
• Business Quant data shows ABCL's Operating Leases at $134.3 million in Q1 2026, $137.4 million in Q4 2025, and $137.1 million in Q3 2025.